Innovating Pharma: Bridging Traditional Acquisition and Emerging Technologies

Abstract

Objective: To explore how large pharmaceutical corporations may integrate emerging decentralized technologies—such as blockchain and DAOs—within their merger, acquisition, and partnership frameworks, and how these strategies intersect with broader innovation and external sourcing models.

Design and Context: This study employed a qualitative case study methodology, combining document analysis and semi-structured interviews with internal stakeholders from a leading large-cap pharmaceutical company (“Company”). Participants included executives and professionals from corporate development, scientific research, external innovation, and digital strategy units. The "Company" operates globally with end-to-end capabilities in drug discovery, development, and commercialization. Data were analyzed using thematic analysis.

Analytical Focus: The analysis examined how a large-cap pharmaceutical company approaches mergers, acquisitions, and partnerships, and how emerging technologies may influence these frameworks. The study focused on strategy alignment, organizational attitudes toward decentralization, integration constraints, and perceptions of the value of innovation along the external sourcing continuum.

Results: The "Company’s" acquisition and innovation strategy is driven by long-term alignment between external opportunities and internal priorities. Over time, the company has increasingly turned to external sources of innovation, supported by substantial investments in AI, big data, and digital platforms. These technologies are leveraged to improve innovation scouting, target identification, and operational forecasting. While decentralization technologies such as DAOs are viewed as promising for early-stage innovation and collaboration, their integration is hindered by legal ambiguity, internal governance rigidity, and unfamiliarity with token-based economics. Company views M&A and licensing as critical to sustaining its pipeline and sees potential for emerging technologies to accelerate preclinical decision-making and improve visibility into academic and biotech ecosystems.

Conclusions: This study contributes insights into how large-cap pharmaceutical firms may adapt their innovation models in response to technological change and external pressures. While established mechanisms such as M&A and partnerships remain dominant, digital and decentralized technologies offer complementary tools for scouting, collaboration, and portfolio expansion. Their integration remains tentative and exploratory, shaped by legal uncertainty, governance complexity, and cultural barriers. Broader comparative research is needed to assess how different firms evaluate and implement these technologies and to determine the long-term feasibility of decentralized governance in the biopharma industry.